Metabolon Files Patent Infringement Lawsuit Against Stemina Biomarker Discovery
Published: Aug 27, 2012
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today that it has filed a patent infringement lawsuit against Stemina Biomarker Discovery, Inc. in the US District Court for the Western District of Wisconsin. The lawsuit seeks a ruling that Stemina’s services directly infringe on US Patent 7,550,258 and US Patent 7,910,301 which relate to global analysis of complex biological samples for the discovery of biomarkers and pathways associated with drug action, toxicity and disease. The lawsuit requests monetary damages as well as an order permanently enjoining Stemina from continued acts of infringement.